Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.
Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp